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The association between decline in physical function and age-related conditions, such
as reduced cognitive performance and vascular disease, may be explained by genetic
influence on shared biological pathways of importance for aging. The apolipoprotein E
(APOE) gene is well-known for its association with Alzheimer’s disease, but has also
been related to other disorders of importance for aging. The aim of this study was to
investigate possible associations between APOE allele status and physical function in
a population-based longitudinal study of older individuals. In 2005, at the age of 75,
622 individuals underwent neuropsychiatric and physical examinations, including tests
of physical function, and APOE-genotyping. Follow-up examinations were performed at
age 79. A significantly larger decline in grip strength (p = 0.015) between age 75 and 79
was found when comparing APOE ε4 allele carriers with non-carriers [10.3 (±10.8) kg
versus 7.8 (±10.1) kg]. No association was seen with decline in gait speed, chair-stand,
or balance. The association with grip strength remained after correction for cognitive
and educational level, depression, cardiovascular disease, stroke, and BMI.
Keywords: physical function, grip strength, gait speed, APOE ε4 allele, dementia
INTRODUCTION
The apolipoprotein (APOE) gene, encoding APOE involved in lipid metabolism, is a well-
established risk factor for Alzheimer’s disease (AD) (Corder et al., 1993; Poirier et al., 1993;
Kandimalla et al., 2011, 2013; Yu et al., 2014). The gene has three common alleles (ε2, ε3, and
ε4), and carriers of the ε2 allele are at lower risk, while ε4 allele carriers are at higher risk, of
the disorder (Bertram et al., 2007). In cognitively healthy individuals, associations between APOE
ε4 and worse performance on cognitive tests, especially in old populations, have been reported
(Caselli et al., 2009; Wisdom et al., 2011; Davies et al., 2014). Further, the ε4 allele is a risk factor
for other conditions that mainly affect older individuals, such as atherosclerosis (Zhu et al., 2016)
and cardiovascular and cerebrovascular disease (Lehtinen et al., 1995; McCarron et al., 1999;
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Zlokovic, 2013). Moreover, in a recent study, our research group
found that APOE ε4 predicts future depression in older persons
(Skoog et al., 2015).
Physical function, objectively assessed by tests of grip strength,
gait speed, chair-stand, and standing balance, has been shown
to be a good predictor of several conditions, such as cognitive
performance (Deary et al., 2006; Boyle et al., 2009), cardiovascular
disease (Leong et al., 2015), activities of daily living (ADL) and
disability, as well as mortality (Abellan van Kan et al., 2009;
Cooper et al., 2010). The association between decline in physical
function and age-related conditions may be explained by genetic
influence on shared biological pathways of importance for aging.
In view of the above mentioned associations between the APOE
gene and several age-related disorders, it is not farfetched to
suggest that this gene also affects physical function.
Few studies on the relation between the APOE gene and
physical function in old age have been performed (Melzer et al.,
2005; Buchman et al., 2009; Batterham et al., 2013; Vasunilashorn
et al., 2013; Verghese et al., 2013; Alfred et al., 2014), and the
results are inconsistent. The purpose of the present study was
to investigate possible associations between APOE allele status
and measures of physical function in a Swedish population-based
longitudinal study of older individuals.
MATERIALS AND METHODS
Study Sample
Participants originate from two epidemiological studies in
Gothenburg, Sweden, the Prospective Population Study
of Women (PPSW) and the Gerontological and Geriatric
Population Studies (H70), which were merged in 2000–2001 to
become one study. The samples have been described in detail
previously (Steen and Djurfeldt, 1993; Bengtsson et al., 1997;
Skoog, 2004; Karlsson et al., 2009). The participants were sampled
from the Swedish Population Register on the basis of birth date
and were born in 1930. Adults living in private households and
in residential care were included. Examinations were done at
an outpatient department or in the participants’ home. In 2005,
there were 1287 eligible individuals and 827 agreed to participate
(response rate 64%). Six hundred and thirty eight individuals
participated in at least one test of physical function, and 622
(97%) of those gave informed consent to participate in genetic
analyses. In 2005, tests of physical function were only done at
the outpatient department. Thus, no individuals were included
among those examined through home visits (n = 129). In 2009,
there were 1108 eligible individuals and 662 agreed to participate
(response rate 60%). Six hundred and ten participated in the
fitness tests and 602 (99%) of them consented to genetic analyses.
In 2009, no tests of gait speed were done among individuals
examined at home visits (n = 197). Among individuals included
in the genetic analyses, 448 participated in at least one test of
physical function in both 2005 and 2009. The study was approved
by the Regional Ethical Review Board in Gothenburg (approval
numbers: S 069-01, T 453-04, 075-09), and written informed
consent was obtained from all participants and/or their relatives
in cases of dementia.
General Examinations and Diagnoses
Clinical examinations included comprehensive social,
functional, physical, neuropsychiatric, and neuropsychological
examinations, as well as close informant interviews (Skoog,
2004). All examinations were carried out by health professionals,
such as nurses or physiotherapists. Dementia was diagnosed
by geriatric psychiatrists according to the Diagnostic and
Statistical Manual of Mental Disorders 3rd Edition Revised
(DSM-III-R; APA, 1987), based on symptoms rated during the
neuropsychiatric examinations and information from the close
informant interviews, as described previously (Skoog et al., 1993,
2015; Guo et al., 2007). Cognitive function was assessed with
the Mini-Mental State Examination (MMSE) (Folstein et al.,
1975). Major and minor depression were diagnosed based on the
neuropsychiatric examination according to the Diagnostic and
Statistical Manual of Mental Disorders 4th Edition (DSM-IV)
(APA, 1994) criteria for minor depression, and Diagnostic and
Statistical Manual of Mental Disorders 5th edition (DSM-5)
(APA, 2013) for major depression. Cardiovascular disease was
defined as angina pectoris according to the Rose criteria (Rose,
1962) and/or myocardial infarction (MI) according to self-
reported history or ECG criteria (Minnesota code 1-1-1 to 1-2-5
or 1-2-7). The diagnosis of stroke/TIA was based on information
from self-reports, close informants and the Swedish hospital
discharge register, as described previously (Liebetrau et al., 2003).
Diabetes was diagnosed based on self-reported history and use
of antidiabetic drugs. Cholesterol was measured with standard
methods at the laboratory at Sahlgrenska University Hospital.
Regarding physical activity, participants were asked about level of
physical activity in their leisure time based on the Saltin–Grimby
Physical Activity Level Scale (Grimby et al., 2015). The scale is a
combined frequency–intensity measure including the following
options: (1) ‘Almost totally inactive’ (e.g., reading, watching TV,
going to the movies), (2) ‘Some physical activity at a minimum
of 4 h/week’ (e.g., bicycling, walking to/from workplace, or
during leisure time, walking with family), (3) ‘Regular physical
activity’ (e.g., gardening, golfing, running, keep-fit exercise,
tennis, dancing), and (4) ‘Regular intense physical activity and
contests’ (e.g., running several times/week, swimming several
times/week, competitive sports).
Tests of Physical Function
Grip strength was tested with a Jamar dynamometer at an elbow
angle of 90 degrees and with the shoulder joint in a neutral
position. The test was repeated three times for each hand,
and the highest value of the best hand was used as outcome
(kg). The method has been shown to have high intra- and
inter-test reliability (Peolsson et al., 2001) and validity (Bellace
et al., 2000). Self-selected and maximum gait speed for 20-
m indoors with standing start (meter/second) were measured
(Frändin and Grimby, 1994). The walking test has shown good
intra- and inter-rater reliability (Connelly et al., 1996). Timed
chair-stand measures mobility by testing the ability to stand up
and sit down from a chair five times in a row as quickly as
possible. The total time (seconds) was used as outcome. The
test displays discriminative and concurrent validity properties
Frontiers in Aging Neuroscience | www.frontiersin.org 2 October 2016 | Volume 8 | Article 225
fnagi-08-00225 September 30, 2016 Time: 17:23 # 3
Skoog et al. APOE and Physical Function in Old Age
(Whitney et al., 2005). Balance was tested by measuring the
ability to stand on one leg without shoes, for a maximum of
30 s (Stones and Kozma, 1987). The test was interrupted if the
individual moved from the standardized position. Three trials for
each leg were allowed, and the best result from the best leg was
used for analysis.
Genotyping
Blood samples were collected and the SNPs rs7412 and
rs429358 in APOE (gene map locus 19q13.2) were genotyped
with KASPar R© PCR SNP genotyping system (LGC Genomics,
Hoddesdon, Herts, UK) or by mini-sequencing (as previously
described in detail; Blennow et al., 2000). Genotype-data for these
two SNPs were used to unambiguously define ε2, ε3, and ε4
alleles. The genotyping success rate was>95% (genotyping failed
for 13 individuals in 2005 and 21 individuals in 2009).
Statistical Analysis
Differences in distribution or mean value of sample
characteristics between age 75 and 79 were investigated
with Fischer’s exact test or t-test, respectively. The relation
between change in physical function, between age 75 and 79, and
APOE ε4 status, as well as cross-sectional associations between
physical function and APOE ε4 status, were analyzed with linear
regressions including sex as a covariate. The association with
change in grip strength was further analyzed using body mass
index (BMI) at baseline (age 75), diabetes at any occasion (i.e.,
at age 75 or 79), total cholesterol at baseline, cardiovascular
disease at any occasion, stroke up to age 79, depression (major
and minor) at any occasion, MMSE score at baseline, change in
MMSE score, and educational level [dichotomized as compulsory
(7 years), or more] as covariates. The cross-sectional association
with grip strength found at age 79 was further analyzed using
BMI at age 79, diabetes at age 79, total cholesterol at age 79,
cardiovascular disease at age 79, stroke up to age 79, depression at
age 79, MMSE score at age 79, and educational level as covariates.
As a first step, both in the longitudinal and cross-sectional
analysis, covariates were included in four different models;
model one included covariates related to cognition (i.e., MMSE
score and educational level), model two included covariates
related to mental health (i.e., major and minor depression),
model three included cardiovascular disease and stroke, and
model four included BMI, diabetes and total cholesterol. As
a final step, all covariates were included in the same model.
Further, all analyses were re-done after excluding individuals
with a dementia diagnosis up to year 2009. In addition, we
performed the analyses only including individuals who reported
that they were physically active (option 2–4 on the Saltin–
Grimby Physical Activity Level Scale), and to be included
in the longitudinal analyses an individual should have been
physically active at both examinations. We also did sensitivity
analyses, where only those who were examined at the out-patient
department were included, as gait speed was not done at any
home visits. All analyses were performed using SPSS version 22
for Windows. The power of the study varied between 90 and
58%, depending on the outcome (largest power for detecting
an association with maximum gait speed and lowest power
for detecting an association with chair-stand). The power-
calculations were based on the assumption that the difference
in decrease between APOE ε4 carriers and non-carriers would
be 3 kg (SD: 10 kg) for grip strength, 0.05 m/s (SD: 0.15 m/s)
for regular gait speed, 0.1 m/s (SD: 0.25 m/s) for maximum gait
speed, 1 s (SD: 4 s) for chair-stand, and 3 s (SD: 10 s) for balance.
The power-calculations were done using SAS version 9.4.
RESULTS
Relevant characteristics of the samples at age 75 and/or 79
are summarized in Table 1. The difference in percentage of
APOE ε4 carriers between age 75 and 79 (Table 1) can at least
partly be explained by the fact that a non-significantly larger
percentage of APOE ε4 carriers, who participated at age 75, had
died or declined to participate at age 79, compared to non-
carriers. A significant association (p= 0.015) was found between
possession of the APOE ε4 allele and larger decline in grip
strength between age 75 and 79 (Table 2). No association was
found between APOE ε4 status and change in gait speed, chair-
stand, or balance. In the cross-sectional analyses, no association
was found between APOE ε4 status and physical function at age
75, while a significant association was found with grip strength
(p = 0.006) at age 79 years (Table 3). Analyses of the interaction
between APOE ε4 and age showed that the effect of the ε4
allele on grip strength was significantly larger at age 79 than
at age 75 (p = 0.033). Both the longitudinal and the cross-
sectional association with grip strength remained after correction
for MMSE score, educational level, depression, cardiovascular
disease, stroke, BMI, diabetes, and total cholesterol. Further,
exclusion of all cases with dementia, or inclusion of only
physically active individuals, did not change the results. Also,
the main results did not change when only individuals who
were examined at the out-patient department were included.
Moreover, after excluding individuals with the ε2ε4 genotype
(n= 6 in the longitudinal analysis and n= 9 in the cross-sectional
analysis at age 79), the relation between grip strength and APOE
ε4 became stronger [mean 19.2 (±10.5) kg for ε4 carriers and 23.0
(±11.9) kg for ε4 non-carriers among 79 year olds (p = 0.001),
and a decline of 11.4 (±9.7) kg for ε4 carriers and 7.8 (±10.1) kg
for ε4 non-carriers (p= 0.001) between 75 and 79 years of age].
DISCUSSION
In this study, we report an association between the APOE ε4 allele
and larger decline in grip strength between age 75 and 79. This
association was independent of cognitive function, as measured
with MMSE, and remained after exclusion of cases with dementia.
A similar result was seen in cross-sectional analyses in the larger
sample of all individuals examined at age 79, showing weaker grip
strength among APOE ε4 carriers compared to non-carriers. No
association with grip strength was seen at age 75, and analyses
of the influence of age revealed that the effect of APOE ε4 was
significantly larger at age 79 compared to age 75.
So far, possible associations between the APOE gene and
measures of physical function in old age have not been
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TABLE 1 | Characteristics of the study sample.
75 year olds
(n with
genotype = 609)
79 year olds
(n with
genotype = 581)
p-value
Women, n (%) 364 (59.8) 347 (59.7) 1.00
APOE ε4 carriers, n (%) 167 (27.4) 118 (20.3) 0.004
Body mass index,
mean (SD)
26.8 (4.2) 26.1 (4.2) 0.007
Cardiovascular
disease∗, n (%)
95 (15.6) 97 (16.7) 0.64
Diabetes, n (%) 78 (12.8) 80 (13.8) 0.67
Cholesterol (mmol/l),
mean (SD)
5.33 (1.07) 5.39 (1.09) 0.34
Stroke, n (%) 52 (8.5) 66 (11.4) 0.12
Dementia, n (%) 16 (2.6) 37 (6.4) 0.002
MMSE, mean (SD) 27.6 (1.8) 27.7 (3.4) 0.52
Education more than
compulsory, n (%)
281 (46.1) 257 (44.2) 0.52
Major depression, n (%) 25 (4.1) 29 (5.0) 0.49
Minor depression, n (%) 85 (14.0) 84 (14.5 0.87
Physical activity∗∗, n (%) 548 (90.0) 500 (86.1) 0.04
Grip strength (kg),
mean (SD)
29.2 (9.9) 22.1 (11.7) <0.0001
Regular gait speed (m/s),
mean (SD)
1.18 (0.19) 1.08 (0.19) <0.0001
Max gait speed (m/s),
mean (SD)
1.64 (0.33) 1.48 (0.31) <0.0001
Chair-stand (s)
mean (SD)
13.3 (4.7) 14.1(5.3) 0.008
Balance (s), mean (SD) 19.6 (10.9) 12.7 (10.8) <0.0001
∗Cardiovascular disease includes as angina pectoris and/or myocardial infarction.
∗∗Physical activity based on the Saltin–Grimby Physical Activity Level Scale (Grimby
et al., 2015), (option 2–4). P-values based on Fischer’s exact test or t-test.
TABLE 2 | Associations between the APOE ε4 allele and change in
physical fitness measures between age 75 and 79.
APOE ε4
carrier
mean (SD)
APOE ε4
non-carrier
mean (SD)
p-value
Grip strength (kg) n = 390 −10.3 (10.8) −7.8 (10.1) 0.015
Regular gait speed (m/s) n = 327 −0.17 (0.16) −0.14 (0.15) 0.18
Max gait speed (m/s) n = 326 −0.25 (0.26) −0.24 (0.23) 0.53
Chair-stand (s) n = 389 1.3 (7.1) 1.1 (4.5) 0.78
Balance (s) n = 347 −9.5 (10.1) −8.9 (10.1) 0.60
P-values based on linear regression analyses adjusted for sex. Significant p-values
are shown in bold.
comprehensively investigated, and results have been inconsistent.
In a study by Batterham et al. (2013), the ε2 allele was found to
be related to a smaller decline in grip strength over a 12-year
period. However, after excluding participants with low cognitive
scores, the finding became non-significant. The study included
individuals aged 70 and older at baseline, but the long follow-
up time included the ages examined in our study. In contrast
to the findings by Batterham et al. (2013), our result remained
significant after correction for cognitive function, and exclusion
of individuals carrying the “protective” ε2 allele strengthened the
association.
Another study reported associations between the ε4 allele and
more rapid motor decline in older individuals (mean age 80 years
at baseline) over a period of 10 years (Buchman et al., 2009). The
composite measure of global motor function used in that study,
included both muscle strength (such as grip strength) and motor
performance (such as gait speed), and the association of ε4 with
motor decline was for the most part explained by an association
with change in muscle strength. In addition, the association
between the ε4 allele and motor function increased with age.
The results of our study are thus in line with the results from
this study, although the participants in the study by Buchman
et al. (2009) were a selected group of individuals who agreed to
post-mortem donation, while our participants are from a general
population.
In our study, no associations were found between APOE
allele status and gait speed or chair-stand. In contrast, Alfred
et al. (2014) studied participants from eight UK cohorts of
the HALCyon program, and found associations between the
APOE ε4 allele and decline in both these measures in one
of the cohorts (age 64–82). However, in the cohort including
individuals aged 77–80 (the Lothian Birth Cohort 1921), which
is most comparable with the ages investigated in our study,
no associations with physical performance could be seen.
Furthermore, in studies only including tests of chair stand time
and/or gait speed, associations with APOE ε4 status have been
reported in individuals older than 65 years (Melzer et al., 2005)
and in men aged 70 years and older (Verghese et al., 2013).
Investigation of the relation between APOE allele status and
physical performance has also been performed in an Asian cohort
(Vasunilashorn et al., 2013). No associations were reported, but
the proportion of participants with the ε4 allele was much lower
in this Asian cohort than in populations of Caucasian origin.
All four measures of physical function (grip strength, gait
speed, chair-stand, and standing balance) investigated in this
study are predictors of all cause mortality in older individuals
from the general population (Cooper et al., 2010). However, the
relative value of gait speed, chair-stand, and balance is unclear,
since these measures are correlated with each other (Cooper et al.,
2010). Grip strength and gait speed are both key components
of sarcopenia (Sayer et al., 2013) and frailty (Fried et al., 2001),
where grip strength is an estimate of overall muscle strength
(Rantanen et al., 1994), while gait speed includes both muscle
strength, balance, motor control, and cardiorespiratory function
(Studenski et al., 2011). Since grip strength is based on decline
in muscle strength only, one might expect to find the clearest
association between the APOE ε4 allele and this measure, like the
result in our study. Still, we cannot give any stable conclusions
regarding the possible association between the APOE ε4 allele and
gait speed, as this test did not include individuals who had home
visits at age 79, and persons with the largest decline in gait speed
might have been missed.
The mechanism behind the relation between the ε4 allele and
motor decline is not clear, but associations have been found with
several different diseases and pathologies which can damage the
widely distributed motor systems in the brain. One is subclinical
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TABLE 3 | Associations between the APOE ε4 allele and measures of physical fitness at age 75 and 79.
75 year olds 79 year olds
APOE ε4 carrier
mean (SD)
APOE ε4
non-carrier
mean (SD)
p-value APOE ε4 carrier
mean (SD)
APOE ε4
non-carrier
mean (SD)
p-value
Grip strength (kg) n = 607 28.9 (9.7) 29.4 (9.9) 0.53 n = 501 19.6 (10.8) 23.0 (11.9) 0.006
Regular gait speed (m/s) n = 597 1.16 (0.20) 1.18 (0.19) 0.35 n = 392 1.06 (0.21) 1.09 (0.18) 0.20
Max gait speed (m/s) n = 596 1.64 (0.35) 1.64 (0.32) 1.00 n = 390 1.47 (0.35) 1.49 (0.29) 0.69
Chair-stand (s) n = 598 13.4 (5.6) 13.2 (4.4) 0.63 n = 496 14.4 (5.2) 14.0 (5.3) 0.50
Balance (s) n = 609 19.3 (11.3) 19.8 (10.7) 0.90 n = 445 13.1 (10.7) 12.6 (10.8) 0.56
P-values based on linear regression analyses adjusted for sex. Significant p-values are shown in bold.
vascular disease, e.g., ischemic white matter changes resulting in
loss of mobility (Rosano et al., 2006), although cerebrovascular
changes may affect gait and balance more than muscle strength.
The relation between the ε4 allele and motor decline may also
be explained by a common association with AD pathology
(Buchman et al., 2009), which has been found not only in brain
regions of importance for cognition, but also in basal ganglia
related to motor function (Wolf et al., 1999; Burns et al., 2005).
The results of our study do not support any of these
hypotheses, since corrections for cardiovascular disease, stroke,
BMI, and cognitive function (MMSE) did not influence the
association between ε4 status and decline in grip strength over
time. In addition, our results did not change after excluding
individuals with dementia. A similar result was shown in the
study by Buchman et al. (2009), when correcting for vascular
factors and mild cognitive impairment. The motor signs that
accompany AD often precede a clinical diagnosis (Boyle et al.,
2009), and we cannot rule out the possibility that the associations
are due to preclinical dementia. However, the results remained
also after controlling for cognitive function in individuals without
dementia, suggesting that the results were not merely due
to incipient dementia. An effect of the APOE gene that is
independent of cognitive function has also been indicated in a
study by Albert et al. (1995), who found an association between
the ε4 allele and poorer functional status among non-demented
older individuals. However, another study detected an association
with functional decline in women only (Blazer et al., 2001), while
a third study found a surprisingly lower chance of having ADL
disability among women homozygous for the ε4 allele (Kulminski
et al., 2008).
Furthermore, previous studies have indicated that a positive
effect of physical activity on age-related changes of the brain,
such as hippocampal atrophy and amyloid burden, as well as
on cognitive decline, is strongest in carriers of the APOE ε4
allele (Head et al., 2012; Woodard et al., 2012; Smith et al.,
2014). However, when performing the analyses in our study after
excluding physically inactive individuals, no main changes of the
results could be seen.
The strengths of our study are the representative population-
based cohort, the comprehensive examinations performed by
trained psychiatric nurses and physiotherapists, and dementia
diagnoses made by geriatric psychiatrists. However, there are also
limitations. One is the relatively short follow-up time, which
makes future dementia impossible to control for. Another is
the relatively small sample size, although previous studies of
associations between physical function in old individuals and
the APOE gene are of similar magnitude. Also, some of the
individuals were investigated either at the age of 75 or the age
of 79, meaning that the cross-sectional analyses partly comprise
different persons. Moreover, the examinations of grip strength,
chair-stand, and balance were performed both at the clinic and
during home visits at age 79, and this might have captured
more diseased or frail individuals compared to age 75 when
the examinations were performed only at the clinic. However,
the association between grip strength and APOE ε4 was still
significant after excluding individuals examined at home visits.
CONCLUSION
Our findings indicate a relation between the APOE ε4 allele
and grip strength in older individuals. However, despite that the
results did not change after controlling for cognitive function
and after excluding cases with dementia, we cannot exclude the
possibility that the weaker grip strength seen among carriers of
the ε4 allele might represent a prodromal symptom of dementia
that will appear later in life.
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